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Tumour growthAccumulation of mast cells (MCs) in tumours was described by Ehrlich in his doctoral thesis. Since this early
account, ample evidence has been provided highlighting participation of MCs to the inﬂammatory reaction
that occurs in many clinical and experimental tumour settings. MCs are bone marrow-derived tissue-homing
leukocytes that are endowedwith a panoply of releasable mediators and surface receptors. These cells actively
take part to innate and acquired immune reactions as well as to a series of fundamental functions such as
angiogenesis, tissue repair, and tissue remodelling. The involvement of MCs in tumour development is
debated. Although some evidence suggests that MCs can promote tumourigenesis and tumour progression,
there are some clinical sets as well as experimental tumour models in which MCs seem to have functions that
favour the host. One of the major issues linking MCs to cancer is the ability of these cells to release potent pro-
angiogenic factors. This review will focus on the most recent acquisitions about this intriguing ﬁeld of
research. This article is part of a Special Issue entitled: Mast cells in inﬂammation.cells in inﬂammation.
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Mast cells (MCs) are bone marrow-derived tissue-homing leuko-
cytes, which were ﬁrst described more than 130 years ago by Paul
Ehrlich in his doctoral thesis [1]. For many decades, these cells have
represented a true enigma for researchers, being implicated in the
pathogenesis of harmful, even lethal, allergic reactions and certain
protective responses to parasites [2]. During the last years, however, a
novel picture of their function has initiated to emerge, which has
profoundly changed our perception of the biological signiﬁcance and
clinical implications of these cells. MCs, indeed, appear now as
ﬂexible, highly versatile tissue-related elements that play an
important role in a large spectrum of biological settings, ranging
from inﬂammation and immune modulation to angiogenesis, tissue
repair, tissue remodelling, and cancer [3,4].
The complex and multifarious function of MCs in the ﬁeld of
tumour growth represents one of the most exciting frontiers in MC
biology. The occurrence of a possible causative link between MCs,
chronic inﬂammation, and cancer has long been suggested. As most
tumours contain inﬂammatory cell inﬁltrates, which often include
plentiful MCs, the question as to the possible contribution of MCs to
tumour development has progressively attracted the attention of
basic and clinical researchers [5–7]. These cells have the capacity tosynthesize and release potent angiogenic compounds [8]. This is a
major point linking MCs to cancer. However, the involvement of MCs
in tumour promotion and expansion is complex and far from being
settled. Although some evidence suggests that MCs can promote
tumourigenesis and tumour progression, there are some clinical sets
as well as experimental tumour models in which MCs seem to have
functions that favour the host [9].
In this review article, the general biology of these cells will be
ﬁrstly and shortly highlighted. Then the importance of angiogenesis in
physiological and inﬂammatory conditions as well as in cancer will be
discussed. Next, the speciﬁc contribution of MCs to angiogenesis in
experimental tumours will be analyzed. Finally, the potential
involvement of MCs in the development of solid and haematological
tumours in different clinical settings will be debated.
2. Mast cell biology
In most histological sections, MCs appear as round or elongated
cells with a diameter ranging between 8 and 20 μm. They are easily
recognized by light microscopy for their plentiful toluidine blue-
positive, metachromatic granules that ﬁll the cytoplasm. MC granules
represent the key functional cell organelles, whose content is
extruded to the cell exterior upon cell activation in the form of either
massive or limited degranulation. The former process is called
exocytosis or anaphylactic degranulation while, for the latter, the
term piecemeal degranulation has been coined [10,11]. As the name
implies, anaphylactic degranulation is a generalized mode of granule
release expressed by MCs during type I allergic reactions. By contrast,
piecemeal degranulation appears as a discrete and selective pathway
3D. Ribatti, E. Crivellato / Biochimica et Biophysica Acta 1822 (2012) 2–8of cell secretion, which is a characteristic trait of MC activation in
chronic inﬂammatory settings, like cancer for instance. In all species
examined, MC granules contain a composite mixture of histamine
(also serotonin in rodents), proteases, cytokines, and growth factors
embedded in a glycosaminoglycan meshwork [12]. Besides the
classical, toluidine blue secretory granules, MCs contain in their
cytoplasm unique lipid bodies that are the source of arachidonic acid
derivatives [11]. In addition, MCs express the tetramericαβγ2 form of
the high-afﬁnity receptor FcεRI for immunoglobulin E (IgE) on their
surface, which is crucial for the activation of the anaphylactic pathway
of cell degranulation [13]. Thus, beyond a series of common features,
MCs show marked differences in their phenotypic expression among
diverse species and anatomical sites, a phenomenon called “MC
heterogeneity” [14,15].
A milestone in our understanding of the biological proﬁle of tissue
MCs was the discovery that these cells originate from haematopoietic
stem cells in the bone marrow, foetal liver, and cord blood. These
progenitor cells circulate in the blood as non-granulated committed
precursors [16–18]. Precursor cells migrate into different tissues in
which they proliferate and differentiate into mature, granulated cells
under the inﬂuence of several microenvironmental growth factors, in
particular stem cell factor (SCF), the ligand for the c-kit tyrosine
kinase III growth factor receptor (CD117) – secreted by ﬁbroblasts,
stromal cells and endothelial cells – which critically regulates many
aspects of MC development and survival [19,20]. Development of
tissue MCs is regulated also by interleukin (IL)-3, IL-4, IL-9, nerve
growth factor (NGF), and probably other factors [21].
MCs display a distinctive pattern of cell distribution throughout
the body. Such localizations enlighten us about some critical functions
expressed by these cells. Two main districts are recognizable: (a) the
body frontiers and (b) the connective tissues. MCs normally reside in
proximity to surfaces that interface the external environment, i.e., the
skin, mucosa of the gastrointestinal, respiratory, and genitourinary
tracts, which are common portals of infection. Thus, MCs are likely to
be among the ﬁrst inﬂammatory cells to interact with invading
pathogens [22]. MCs also populate the connective tissue structures
near vessels and nerves, in a position that makes them key elements
in processes like tissue remodelling, wound healing, ﬁbrosis, and
angiogenesis [23,24]. MCs have also been found in the central nervous
system of several vertebrate species, where they provide putative
functions that still await elucidation [25]. By contrast, MCs are not
found in avascular tissues such as mineralized bone, cartilage, and the
cornea.
MCs represent a rich source of biologically active mediators, which
are either preformed in their granules or synthesized de novo [26,27].
The cross-linking of IgE with bivalent or multivalent antigens results
in the aggregation of FcεRI, which is sufﬁcient for initiating
downstream signal transduction events that activate cell degranula-
tion as well as the de novo synthesis and secretion of lipid mediators
and cytokines [28]. Release of preformed and newly formed MC
products from activated MCs leads to a series of profound biological
effects. MCs may also be activated by “alternative”, IgE-independent
pathways, such as aggregation of FcγRIII by IgG/antigen complexes,
c-kit and Toll-like receptor mechanisms, exposure to chemokines,
anaphylatoxins C3a and C5a, fragments of ﬁbrinogen and ﬁbronectin
[29–31].
MC mediators affect several aspects of inﬂammation and immune
response, enabling these cells to act as important sentinels of the
immune system. Thus, MCs are crucial cells in the initiation of both
innate and acquired host defence against various pathogens. They are
capable of recognizing, attaching to, phagocytosing, and directly
killing a wide variety of opsonized Gram-negative and Gram-positive
bacteria [32]. They recognize pathogens through pattern-recognition
receptors (Toll-like receptors) and can respond with the induced
expression of tumour necrosis factor (TNF)-α, type I interferons, and
other inducible cytokines (IL-4, IL-6, IL-8) and chemotactic mediators(CCL3, CCL5, CXCL8) linked to the innate host response [31,33]. They
also contribute to optimal initiation of acquired immunity by
orchestrating migration, maturation, and function of dendritic cells
and by interacting with T and B cells [34,35]. There are indications,
however, that MCs may cause detrimental effects in virus infections
by acting as a virus reservoir or helping viruses such as HIV-1, Dengue
virus, cytomegalovirus, and adenovirus, by eluding immunosurveil-
lance and hastening the inﬂammatory response [36]. In vitro
experiments suggest that as MCs express MHC class I and II molecules,
they can also act as antigen presenting cells and/or represent sources
of co-stimulatory activity (e.g., by expressing CD40 or its ligand) [37].
MCs also affect tissue homeostasis, remodelling, repair, and
ﬁbrosis [38–40]. These functions are accomplished by a direct MC
stimulation of speciﬁc connective tissue cell types, in particular
ﬁbroblasts, and by the release or activation of a series of extracellular
matrix (ECM)-degrading enzymes. In addition, MCs synthesize and
release many angiogenic growth factors, which exert important
functions on blood and lymphatic vessel development.
Human MCs are conventionally divided into two types depending
on the expression of different proteases in their granules and other
functional features [41]. MCs, which contain tryptase only, are
designated as MCT or “immune cell associated” MCs. They are
predominantly located in the respiratory and intestinal mucosa,
where they co-localize around T lymphocytes. MCs that contain both
tryptase and chymase, along with other proteases such as carboxypep-
tidase A and cathepsin G, are referred to as MCTC. They are
predominantly found in connective tissue areas, such as skin,
submucosa of stomach and intestine, breast parenchyma, myocardium,
lymph nodes, conjunctiva, and synovium. These two subsets of human
MCs differ also in terms of their mediator content and reactivity. A third
type of MC, calledMCC, has been identiﬁed. This MC expresses chymase
without tryptase and resides mainly in the submucosa and mucosa of
the stomach, small intestinal submucosa, and colonic mucosa [42].3. The importance of angiogenesis in physiological and
pathological conditions
Angiogenesis, i.e., the formation of new vessels from pre-existing
ones – such as capillaries and post-capillary venules – plays a pivotal
role during embryonic development [43]. Later, in adult life,
angiogenesis occurs in several physiological (e.g., corpus luteum
formation) and pathological conditions, such as tumour and chronic
inﬂammation, where it may contribute to the progression of disease.
In 1971, Folkman published in the New England Journal of Medicine
a hypothesis that tumour growth is angiogenesis-dependent and that
inhibition of angiogenesis could be therapeutic [44]. This paper also
introduced the term antiangiogenesis to mean the prevention of new
vessel sprout from being recruited by a tumour. The hypothesis
predicted that tumours would be unable to grow beyond a
microscopic size of 1 to 2 mm3 without continuous recruitment of
new capillary blood vessels. Even if the majority of pre-clinical studies
have shown that the growth of all experimental tumours can be
effectively inhibited by various antiangiogenic agents, the clinical
beneﬁts of antiangiogenic treatments are relativelymodest, and in the
majority of cases, the drugs merely slow down tumour progression
and prolong survival by only a few more months [45].
Under physiological conditions, angiogenesis is dependent on the
balance of positive and negative modulators within the vascular
microenvironment [46] and requires the functional activities of a
number of molecules, including angiogenic factors, extracellular
matrix proteins, adhesion receptors, and proteolytic enzymes. As a
consequence, angiogenic endothelial cells have a distinct gene
expression pattern that is characterized by a switch of the cell
proteolytic balance towards an invasive phenotype as well as by the
expression of speciﬁc adhesion molecules. In normal tissues, vascular
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angiogenesis inhibitors over angiogenic stimuli [47].
Pathological angiogenesis is linked to a switch in the balance
between positive and negative regulators and mainly depends on the
release by inﬂammatory or neoplastic cells of speciﬁc growth factors
for endothelial cells that stimulate the growth of the host's blood
vessels or the down-regulation of natural angiogenesis inhibitors [48].
Tumour blood vessels display many structural and functional
abnormalities. They are irregular in size, shape, and branching
pattern; lack the normal vessel hierarchy; and do not display the
recognizable features of arterioles, capillaries, and venules [49]. Like
normal blood vessels, they consist of endothelial cells, mural cells, and
their enveloping basement membrane but each component of the
vessel wall presents abnormalities. Tumour-associated endothelial
cells proliferate 50–200 times faster than normal endothelial cells.
They form a structurally defective endothelium, which shows
discontinuities or gaps that allow haemorrhage and facilitate
permeability of macromolecules and the trafﬁc of tumour cells into
the bloodstream. The basement membrane that envelops endothelial
cells and pericytes of tumour vessels may have extra layers that have
no apparent association with the cells. Pericytes of tumour vessels are
loosely associated with endothelial cells, have abnormal shape,
paradoxically extend cytoplasmic processes away from the vessel
wall, and have extra layers of loosely ﬁtting basement membrane.
Thus, tumour vasculature is typically aberrant, disordered, and leaky.
4. The contribution of immune cells to angiogenesis in
inﬂammation and tumour growth
There is increasing evidence to support the view that angiogenesis
and inﬂammation are mutually dependent [50]. During inﬂammatory
reactions, immune cells synthesize and secrete pro-angiogenic factors
that promote neovascularization. On the other hand, the newly
formed vascular supply contributes to the perpetuation of inﬂamma-
tion by promoting the migration of inﬂammatory cells to the site of
inﬂammation [50]. The extracellular matrix and basement membrane
are a source for endogenous angiogenesis inhibitors. On the other
hand, many extracellular matrix molecules promote angiogenesis by
stabilizing blood vessels and sequestering angiogenic molecules [51].
It is well established that tumour cells are able to secrete pro-
angiogenic factors as well as mediators for inﬂammatory cells [48].
They produce indeed angiogenic cytokines, which are exported from
tumour cells or mobilized from the extracellular matrix. As a
consequence, tumour cells are surrounded by an inﬁltrate of
inﬂammatory cells. These cells communicate via a complex network
of intercellular signaling pathways, mediated by surface adhesion
molecules, cytokines, and their receptors [52]. Immune cells cooper-
ate and synergize with stromal cells as well as malignant cells in
stimulating endothelial cell proliferation and blood vessel formation.
These synergies may represent important mechanisms for tumour
development and metastasis by providing efﬁcient vascular supply
and easy pathway to escape. Indeed, the most aggressive human
cancers are associated with a dramatic host response composed of
various immune cells, especially macrophages and MCs [50].
5. Mast cells and angiogenesis
MCs produce a large spectrum of pro-angiogenic factors. Human,
rat, and mouseMCs release preformed ﬁbroblast growth factor (FGF)-
2 from their secretory granules [53,54]. Human cord blood-derived
MCs release vascular endothelial growth factor (VEGF) upon
stimulation through FcεRI and c-kit. Both FGF-2 and VEGF have also
been identiﬁed by immunohistochemistry in mature MCs in human
tissues [55,56]. HumanMCs are a potent source of VEGF in the absence
of degranulation through activation of the EP(2) receptor by PGE2
[57]. Following IgE-dependent activation MCs released several pro-angiogenic mediators stored in their granules, such as VEGF [58] and
FGF-2 [59], that promote angiogenesis even in the early phase of
allergic inﬂammation. MCs can also migrate in vivo [60] and in vitro
[61] in response to VEGF. Human lung MCs express VEGF-A, VEGF-B,
VEGF-C, and VEGF-D at both mRNA and protein level. PGE2 enhanced
the expression of VEGF-A, VEGF-B, and VEGF-C, whereas an adenosine
analog (5′-[N-ethylcarboxamido] adenosine [NECA]) increased VEGF-
A, VEGF-C, and VEGF-D expression [62]. In addition, supernatants of
PGE2- and NECA-activated human lung MCs induced angiogenic
response in the chorioallantoic membrane (CAM) assay that was
inhibited by an anti-VEGF-A antibody. Finally, placental growth
factor-1 induced MC chemotaxis [62].
Granulated MCs and their granules, but not degranulated MCs, are
able indeed to stimulate an intense angiogenic reaction in the chick
embryo CAM assay. This angiogenic activity is partly inhibited by anti-
FGF-2 and -VEGF antibodies, suggesting that these cytokines are
involved in the angiogenic reaction [63]. Similarly it has been
demonstrated, using the rat-mesenteric window angiogenic assay,
that intraperitoneal injection of compound 48/80 causes a vigorous
angiogenic response [64]. The same treatment in mice also causes
angiogenesis [65].
MCs store large amounts of preformed active serine proteases,
such as tryptase and chymase, in their secretory granules [66].
Tryptase stimulates the proliferation of endothelial cells, promotes
vascular tube formation in culture, and also degrades connective
tissue matrix to provide space for neovascular growth. Tryptase also
acts indirectly by activating latent matrix metallo-proteases (MMPs)
and plasminogen activator (PA), which in turn degrade the extracel-
lular connective tissue with consequent release of VEGF or FGF-2 from
their matrix-bound state [67]. MC-derived chymase degrades extra-
cellular matrix components, and therefore, matrix-bound VEGF could
be potentially released.
Histamine and heparin stimulated proliferation of endothelial cells
induced the formation of new blood vessels in the CAM assay [68,69].
Histamine stimulates new vessel formation by acting through both H1
and H2 receptors [69]. Heparin may act directly on blood vessels or
indirectly by inducing release of FGF-2 from the extracellular storage
site. In addition, other cytokines produced by MCs, such as IL-8 [70],
TNF-α [71], transforming growth factor (TGF)-β, NGF [72], and
urokinase-type PA have been implicated in normal and tumour-
associated angiogenesis [73]. Lastly, MCs also contain preformed
MMPs, such as MMP-2 and MMP-9, and TIMPs, which enable MCs to
directly modulate extracellular matrix degradation. This, in turn,
allows for tissue release of extracellular matrix-bound angiogenic
factors.
6. Mast cell recruitment to tumour
It has recently been recognized that a condition of chronic
inﬂammation stimulates proliferation of resident tissue MCs and
promotes the local recruitment of circulating MC precursors [18,74].
This occurs during tumour development, whereby MCs form one of
the major inﬂammatory cell populations and are now considered
critical regulators of inﬂammation and the immunological response in
the tumour microenvironment.
Huang and co-workers [75] were able to demonstrate that in a
hepatocarcinoma model, MCs failed to migrate into SCF-knockdown
tumours and anti-c-kit antibodies abolished the migration of MCs into
tumours, leading to decreased tumour growth. This indicates that
recruitment and activation of MCs in the tumour inﬁltrate are mainly
mediated by tumour-derived SCF and its receptor c-kit on MCs. In the
same experimental model, SCF stimulates the chemotactic migration
of MCs. Some effects of SCF stimulation depend on the concentration
of the cytokine. Low SCF concentrations induce the release of active
MMP-9 into the local environment, while higher SCF concentrations
promote activation in the tumour context of recruited MCs and the
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NOS, and CCL-2 [75]. Activation of MCs by SCF has important
consequences for tumour growth. Indeed, SCF-activated MCs in the
tumour microenvironment increased the transcription of IL-17 gene
and the amount of IL-17-producing cells in the tumour mass. In turn,
IL-17 – a potential candidate for regulating the tumour inﬂammatory
reaction through the production of IL-9 – would attract more MCs at
the site of inﬂammation [76]. In addition, TNF-α and other
proinﬂammatory factors released by MCs can increase the activity of
NK-κB and AP-1 in tumour cells [75]. NK-κB and AP-1, in turn, may
favour the proliferation of tumour cells by inducing the expression of
cyclines, the surviving of tumour cells by the blockade of apoptosis,
and the invasiveness of tumour cells by inducing the production of
MIF and EMMPRIN [77,78].
7. Mast cells and tumour angiogenesis
An increased number of MCs have been reported in angiogenesis
associated with vascular neoplasms, as well as a number of solid and
haematological tumours [79]. Ehrlich was the ﬁrst to ﬁnd that MCs
accumulate in tumours, especially carcinomas [80], but it was his
pupil, Westphal, who recognized that MCs tended to gather at the
periphery of carcinomatous nodules, rather than in the core of a
tumour [81].
Experimentally induced tumours displayMC accumulation close to
the tumour cells before the onset of angiogenesis [82]. Likewise, an
increase in MC number has been observed in tumour invasion around
rat mammary adenocarcinoma [83]. Early studies in experimentally
induced epidermoid carcinoma in hamster buccal pouches by
repeated topical application of dimethylbenzanthracene demonstrat-
ed sequential MC migration towards progressive mucosal dysplasia
and subsequent development of squamous cell carcinoma [84].
Development of squamous cell carcinoma in a human papilloma
virus (HPV) 16- transgenic mouse model of epithelial carcinogenesis,
obtained by transgenic expression of the early region of HPV type 16
in the basal cells of the squamous epithelium in transgenic mice using
a human keratin 14 promoter, provided elegant experimental clues in
favour of an early participation of MCs andMC-related angiogenesis in
tumour growth [85]. Inﬁltration by MCs and activation of MMP-9
coincided with the angiogenic switch in premalignant lesions. MCs
inﬁltrated hyperplasias, dysplasias, and the invasive front of carcino-
mas, but not the core of solid tumours, and were seen to degranulate
in close apposition to capillaries and epithelial basement membranes,
releasing tryptase and chymase. Remarkably, premalignant angio-
genesis was abolished in a MC-deﬁcient HPV16 transgenic mouse
indicating that neoplastic progression in this model involved
participation of MC inﬁltrating the skin.
It is generally accepted that most colon cancers develop from
adenomatous polyps, and it has been demonstrated in mice that, from
the onset, polyps are inﬁltrated with proinﬂammatory MCs and their
precursors [86]. Depletion of MCs either pharmacologically or through
the generation of chimeric mice with genetic lesions in MC
development leads to a profound remission of existing polyps,
suggesting that MCs are an essential haematopoietic component for
preneoplastic polyp development as well as a possible target for
therapeutic intervention.
In a pancreatic β-cell tumour model, activation of Myc in vivo has
been shown to trigger rapid recruitment of MCs to the tumour site,
recruitment that is absolutely required for macroscopic tumour
expansion [87]. In addition, treatment of established β-cell tumours
with cromolyn, an inhibitor of MC degranulation, rapidly triggers
hypoxia and cell death of tumour and endothelial cells. Similarly,
activation of Myc in β-cells of genetically MC-deprived mice does not
elicit any measurable β-cell or islet expansion.
Experimental evidence indicates that angiopoietin-1 (Ang-1)
secreted by primary murine MCs promotes marked neovasculariza-tion in an in vivo transplantation assay [88]. Primary MCs accelerate
tumour growth by established plasmacytoma cell lines and the use of
Ang-1-neutralizing antibodies reduces signiﬁcantly the growth of
plasmacytomas containing MCs.
In tumours, MCs are recruited and activated via several factors
secreted by tumour cells. One of the most important is the SCF
[89,90]. Besides the SCF, other MC-recruiting and/or -activating
factors have been identiﬁed, namely FGF-2, VEGF, platelet-derived
endothelial cell growth factor (PD-ECGF), RANTES and monocyte
chemotactic protein (MCP)-1, adenosine, and adrenomedullin
[91–93].
Association between MCs and new vessel formation has been
reported in breast cancer [94,95], colorectal cancer [96], and uterine
cervix cancer [97]. Tryptase-positive MCs increase in number and
vascularization increases in a linear fashion from dysplasia to invasive
cancer of the uterine cervix [98]. An association of VEGF andMCs with
angiogenesis has been demonstrated in laryngeal carcinoma [99] and
in small lung carcinoma, where most intratumoural MCs express
VEGF [100–102]. MC accumulation has also been noted repeatedly
around melanomas, especially invasive melanoma [103,104]. MC
accumulation was correlated with increased neovascularization, MC
expression of VEGF [105] and FGF-2 [106], tumour aggressiveness,
and poor prognosis. Indeed, a prognostic signiﬁcance has been
attributed to MCs and microvascular density not only in melanoma
[107] but also in squamous cell cancer of the oesophagus [108].
Recently, angiogenesis has been shown to correlate with tryptase-
positive MC count in human endometrial cancer. Both parameters
were found to increase in agreement with tumour progression [109].
MC density, new vessel rate, and clinical prognosis have also been
found to correlate in haematological tumours. In benign lymphade-
nopathies and B cell non-Hodgkin's lymphomas, angiogenesis
correlates with total and tryptase-positive MC counts, and both
increase in step with the increase with malignancy grades [110,111].
In non-Hodgkin's lymphomas, a correlation has been found between
vessel count and the number of MCs and VEGF-expressing cells [112].
In the bone marrow of patients with inactive and active multiple
myeloma as well as those with monoclonal gammopathies of
undetermined signiﬁcance, angiogenesis highly correlates with MC
counts [113]. A similar pattern of correlation between bone marrow
microvessel count, total and tryptase-positive MC density and tumour
progression has been found in patients with myelodysplastic
syndrome [114] and B cell chronic lymphocytic leukemia [115]. In
the early stages of B cell chronic lymphocytic leukemia, the density of
tryptase-positive MCs in the bone marrow has been shown to predict
the outcome of the disease [116].
8. Conclusions
MCs appear as important elements in tumour development and
progression. Their early recruitment in the tumourmicroenvironment
and the multifarious functions they are able to express justify the
increasing interest these cells have been attracting in this ﬁeld of
research. The literature is rich of investigations on MC engagement in
different tumour settings. Data, however, are somewhat contradicto-
ry, and MC effects on tumour fate have been described as either
positive or negative, depending upon the different clinical or
experimental context. Indeed, correlation between their number
and prognosis in various human tumour types shows some dis-
crepancies, which are recognizable also in experimental studies of
carcinogenesis.
Literature data converge in indicating MCs as a key source of
angiogenic and tissue remodelling factors in the tumour milieu. This
appears as a primary contribution of MCs to tumour development. But
it is not the only one (Fig. 1). Once recruited in the tumour context,
MCsmay either play additional roles by attracting other inﬂammatory
cells or, alternatively, suppress anti-tumoural responses. MCs, indeed,
Fig. 1. Drawing illustrating the complex role of MCs in the tumour scenario. Mast cells attracted in the tumour context by SCF secreted by tumour cells produce several angiogenic
factors – such as VEGF, FGF-2, IL-8, tryptase, chymase, NGF, heparin, and TGF-β – as well as matrix metallo-proteases, like MMP-2 andMMP-9, which promote tumor vascularization
and tumor invasiveness, respectively. MCs may also generate immunosuppression by releasing IL-10, histamine, and TNF-α. MCs inﬁltrating the tumor stroma favour expansion and
activation of regulatory T cells (T reg cells), which, in turn, stimulate immune tolerance and tumor promotion. By contrast, MCs may promote inﬂammation, inhibition of tumor cell
growth, and tumor cell apoptosis by releasing cytokines such as IL-1, IL-4, IL-6, IL-8, MCP-3, MCP-4, INF-α, TNF-α, TGF-β, LTB4, and chymase. TNF-α, in particular, is very effective in
leukocyte chemoattraction. Abbreviations: SCF, stem cell factor; VEGF, vascular endothelial growth factor; IL-8, interleukin-8; FGF-2, ﬁbroblast growth factor-2; NGF, nerve growth
factor; TGF-β, transforming growth factor-β; MMP-2, MMP-9, matrix metallo-protease 2, -9; MCP-3, MCP-4, mast cell protease-3, -4; TNF-α, tumor necrosis factor-α; INF-α,
interferon-α; LTB4, leukotriene B4.
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These cells not only produce inhibitory cytokines, such as IL-10 [118],
but also are essential in promoting the immune tolerancemediated by
regulatory T (Treg) cells. Indeed, MCs serve as enforcers for Treg cells,
turning down the immune system's reaction to skin allograft possibly
by IL-10 secretion [119]. Thus, the pivotal role of MCs in the induction
of an acquired condition of immune tolerance may be critical for
sustaining tumour growth.
The potential implication of MCs in tumour biology has stimulated
the production of drugs or experimental procedures leading to MC
depletion or inhibition of MC secretion. Indeed, MCs might act as a
new target for the adjuvant treatment of tumours through the
selective inhibition of angiogenesis, tissue remodelling and tumour-
promoting molecules, permitting the secretion of cytotoxic cytokines
and preventing MC-mediated immune suppression. Preliminary
studies using anti-c-kit antibodies [75], anti-TNF-α antibodies [120],
or the MC stabilizer disodium cromoglycate (cromolyn) [121] in
mouse models have demonstrated promising results even if admin-
istered after the initiation of tumour development. Further studies
will hopefully shed light on these important aspects of MC biology.
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